FDA Approves Once-Every-Four-Weeks Maintenance Dosing Of LEQEMBI For Early Alzheimer's Disease
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced Sunday that the U.S. Food and Drug Administration has approved the ...
Biogen Inc.: FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...
WVU Cancer Institute offers pioneering lung cancer treatment
The WVU Cancer Institute is the first provider in the state to offer a new and promising treatment for extensive-stage small cell lung cancer. Extensive stage means the cancer has spread within the ...
New cancer treatment can cure cancer in less than a second
Flash radiotherapy could replace conventional cancer treatments. It delivers radiation ultra-fast, reducing treatment ...
With her cancer in remission, the Princess of Wales finds a new role and focus
As Catherine, Princess of Wales, becomes joint patron of the hospital where she received her chemotherapy treatment for cancer, she signals the importance that role could hold for her in the future.